Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9403491 | 0.96 | TSHR (0.39) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL3388692 | 0.80 | TSHR (0.42) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL9957770 | 0.80 | TSHR (0.42) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL25416146 | 0.76 | SLC18A3 (0.40) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL3382310 | 0.73 | LMNA (0.39) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL1809933 | 0.72 | CTSL (0.45) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL18616170 | 0.72 | OPRM1 (0.40) | CTSLCTSBCTSKHRH3TACR1 | |
| SCHEMBL31455123 | 0.72 | CYP2C9 (0.42) | TAAR1LMNATSHRCTSLCTSB | |
| SCHEMBL28322822 | 0.70 | OPRM1 (0.39) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL4677170 | 0.70 | TSHR (0.54) | TAAR1LMNATSHRCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| EP-1914232-B1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1914232-A1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-7300947-B2 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | TAAR1 35/4885LMNA 2643/4885TSHR 351/4885 |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | TAAR1 647/4885LMNA 4784/4885TSHR 168/4885 |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | TAAR1 35/4885LMNA 2643/4885TSHR 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.